A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 30 Mar 2017
Price : $35 *
At a glance
- Drugs Talazoparib (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms PANDA
- 16 Dec 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, according to United Kingdom Clinical Research Network record.
- 14 Dec 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
- 21 Jul 2015 UKCRN reports closure date as 30 Aug 2017.